Skip to content

the Effect Between Platelet Reactivation and Antiplatelet Drugs

Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02198053
Enrollment
74
Registered
2014-07-23
Start date
2014-05-31
Completion date
2015-12-31
Last updated
2015-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Effect Disorder, Platelet Procoagulant Activity Deficiency

Brief summary

Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is more powerful antiplatelet drug. However, because of increased bleeding and dyspnea risk, both loading double dose and following second dose time had potential risk and inconvenient in routine clinical work, especially in elective PCI of comparable stable patients in Chinese. The benefit and risk should be balanced in such patients. The investigators supposed loading single dose and followed by second routine time dose was superior to clopidogrel and safer than ticagrelor previously prescribed.

Detailed description

All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period. Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.

Interventions

None listed

Sponsors

Beijing Anzhen Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

coronary artery disease, percutaneous coronary intervention

Exclusion criteria

high risk bleeding patient, allergic to the drugs

Design outcomes

Primary

MeasureTime frameDescription
Platelet reactivity1 yearLTA and TEG used to measure the effect of Platelet reactivity

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026